FACTORS ASSOCIATED WITH INCONSISTENT DORNASE ALFA THERAPY IN PATIENTS WITH CYSTIC FIBROSIS

被引：0

作者：

Sawicki, G. S. ^{[1
]}

VanDevanter, D. ^{[2
]}

Schechter, M. S. ^{[3
]}

Millar, S. ^{[4
]}

Xu, Y. ^{[5
]}

Pasta, D. ^{[4
]}

Morgan, W. ^{[6
]}

Konstan, M. ^{[2
]}

机构：

[1] Childrens Hosp, Boston, MA 02115 USA

[2] Case Western Reserve Univ, Sch Med, Cleveland, OH USA

[3] Emory Univ, Sch Med, Atlanta, GA USA

[4] ICON Late Phase & Outcomes Res, San Francisco, CA USA

[5] Genentech Inc, San Francisco, CA 94080 USA

[6] Univ Arizona, Tucson, AZ USA

来源：

PEDIATRIC PULMONOLOGY | 2012年 / 47卷

关键词：

D O I：

暂无

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

引用

页码：356 / 356

页数：1

共 50 条

[31] Early treatment with dornase alfa in cystic fibrosis: What are the issues?
Bush, A
PEDIATRIC PULMONOLOGY, 1998, 25 (02) : 79 - 82
[32] THE EFFECT OF INTRANASAL DORNASE ALFA ON CHRONIC SINUSITIS IN PATIENTS WITH CYSTIC FIBROSIS: A PILOT STUDY
Lahiri, T.
Herrington, H.
Diehl, S.
Landrigan, G.
PEDIATRIC PULMONOLOGY, 2012, 47 : 354 - 354
[33] ASSOCIATION OF DORNASE ALFA (PULMOZYME) ADHERENCE WITH MULTIPLE CLINICAL OUTCOMES IN PATIENTS WITH CYSTIC FIBROSIS
Schwartz, M. S.
Warren, W.
McClure, M.
Greene, C.
Graff, G.
PEDIATRIC PULMONOLOGY, 2010, : 369 - 369
[34] Dornase alfa in the treatment of cystic fibrosis in Europe: A report from the Epidemiologic Registry of Cystic Fibrosis
Hodson, ME
McKenzie, S
Harms, HK
Koch, C
Mastella, G
Navarro, J
Strandvik, B
PEDIATRIC PULMONOLOGY, 2003, 36 (05) : 427 - 432
[35] THE COST EFFECTIVENESS OF DORNASE ALFA VERSUS INHALED TOBRAMYCIN IN THE MANAGEMENT OF PATIENTS WITH CYSTIC FIBROSIS
Rezaei, S.
Taheri, S.
Yousefi, N.
Peiravian, F.
VALUE IN HEALTH, 2019, 22 : S876 - S876
[36] Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation
Bakker, E. M.
Volpi, S.
Salonini, E.
van der Wiel-Kooij, E. C.
Sintnicolaas, C. J. J. C. M.
Hop, W. C. J.
Assael, B. M.
Merkus, P. J. F. M.
Tiddens, H. A. W. M.
EUROPEAN RESPIRATORY JOURNAL, 2011, 38 (06) : 1328 - 1335
[37] Pharmacoeconomic Assessment of the Application of Dornase Alfa in the Treatment of Lung Generation in Patients with Cystic Fibrosis
Nemchenko, Alla S.
Panfilova, Anna L.
Podgaina, Maryna V.
Zaytzeva, Yuliya L.
Balynska, Maryna V.
ASIAN JOURNAL OF PHARMACEUTICS, 2018, 12 (01) : 374 - 381
[38] DORNASE ALFA FOR CYSTIC-FIBROSIS - PATIENTS SHOULD NOT BE DENIED A SAFE, EFFECTIVE TREATMENT
HODSON, ME
ROSENTHAL, M
WALLIS, C
STABLEFORTH, DE
CONWAY, SP
LITTLEWOOD, JM
BRITISH MEDICAL JOURNAL, 1995, 310 (6993): : 1533 - 1533
[39] Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis
Voldby, Christian
Green, Kent
Philipsen, Lue
Sandvik, Rikke Mulvad
Skov, Marianne
Buchvald, Frederik
Pressler, Tacjana
Nielsen, Kim Gjerum
JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (06) : 949 - 956
[40] Dornase Alfa for Non-Cystic Fibrosis Pediatric Pulmonary Atelectasis
Thornby, Krisy-Ann
Johnson, Ashley
Axtell, Samantha
ANNALS OF PHARMACOTHERAPY, 2014, 48 (08) : 1040 - 1049

← 1 2 3 4 5 →